GreenPharm has developed a monoclonal antibody (mAb)-based post-exposure prophylaxis against rabies, which is an acute viral disease transmitted through the bite of rabid animals. The unique cocktail of two potent mAB’s, known as Rabivir™, will replace the current post-exposure treatment which uses human or equine rabies immune globulin. GreenPharm offers a new, scalable manufacturing technology that makes use of transient expression for rapid expression of product. This proprietary manufacturing platform will substantially lower the manufacturing cost and this is likely to allow RabiVir™ to be a better priced product for the combat of rabies in developing countries.